Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma

Clinical Endocrinology

Volumn 86, Issue 4, 2017, Pages 614-620

  Morganstein, D L ^a,b   Lai, Z ^a,b   Spain, L ^a   Diem, S ^a,c,d   Levine, D ^a   Mace, C ^b   Gore, M ^a   Larkin, J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d Breast Center   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PERTECHNETIC ACID TC 99M; PROGRAMMED DEATH 1 RECEPTOR; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE; CTLA4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLLIMATOR; CORTICOSTEROID THERAPY; DRUG UPTAKE; DRUG USE; FEMALE; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; MIDDLE AGED; PRIORITY JOURNAL; SUBCLINICAL HYPERTHYROIDISM; SUPRAVENTRICULAR TACHYCARDIA; THYROID DISEASE; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; PATHOPHYSIOLOGY; THYROID FUNCTION TEST;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; THYROID DISEASES; THYROID FUNCTION TESTS;

EID: 85011339270     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.13297     Document Type: Article

References (16)

1. Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363, 711–723.
2. Robert, C., Thomas, L., Bondarenko, I. et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364, 2517–2526.
3. Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J. et al. (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncology, 16, 522–530.
4. Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J. et al. (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. New England Journal of Medicine, 375, 1845–1855.
5. Robert, C., Schachter, J., Long, G.V. et al. (2015) Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine, 372, 2521–2532.
6. Larkin, J., Chiarion-Sileni, V., Gonzalez, R. et al. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine, 373, 23–34.
7. Albarel, F., Gaudy, C., Castinetti, F. et al. (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. European Journal of Endocrinology, 172, 195–204.
8. Faje, A.T., Sullivan, R., Lawrence, D. et al. (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. Journal of Clinical Endocrinology and Metabolism, 99, 4078–4085, jc20142306.
9. Ryder, M., Callahan, M., Postow, M.A. et al. (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-Related Cancer, 21, 371–381.
10. Borodic, G., Hinkle, D.M. & Cia, Y. (2011) Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plastic and Reconstructive Surgery, 27, e87–e88.
11. Postow, M.A., Chesney, J., Pavlick, A.C. et al. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New England Journal of Medicine, 372, 2006–2017.
12. Orlov, S., Salari, F., Kashat, L. et al. (2015) Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. Journal of Clinical Endocrinology and Metabolism, 100, 1738–1741.
13. de Filette, J., Jansen, Y., Schreuer, M. et al. (2016) Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. Journal of Clinical Endocrinology and Metabolism, 101, 4431–4439, jc20162300.
14. Lee, W.R., Pease, A.P. & Berry, C.R. (2010) The effects of iohexol administration on technetium thyroid scintigraphy in normal cats. Veterinary Radiology & Ultrasound, 51, 182–185.
15. Kowasky, R. & Falen, S. (2004) Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine. The American Pharmacists Association, Washington, DC.
16. Min, L., Hodi, F.S., Giobbie-Hurder, A. et al. (2015) Systemic high dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clinical Cancer Research, 21, 749–755.